Physician profile
Frank A Lopez
NPI 1154453397
$484,331.87
in general payments reported to CMS, 2019-2025
31 companies · $50K in 2025
The $50K reported for 2025 was more than what 95% of Neurodevelopmental Disabilities (Pediatrics) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156K · 2020: $66K · 2021: $33K · 2022: $66K · 2023: $53K · 2024: $60K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Honoraria: $49K · Travel and Lodging: $9,863 · Consulting Fee: $8,573 · Food and Beverage: $7,434 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,918.00 |
| Honoraria | $49,130.00 |
| Travel and Lodging | $9,863.11 |
| Consulting Fee | $8,573.00 |
| Food and Beverage | $7,434.46 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $287,151.81 | 2019-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $160,419.09 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $15,213.84 | 2025 | Jornay Pm |
| Tris Pharma INC | $8,841.46 | 2019-2025 | Onyda Xr |
| Otsuka America Pharmaceutical, INC. | $6,819.96 | 2024 | |
| Neos Therapeutics, Lp | $2,514.11 | 2019 | |
| Corium, LLC | $920.00 | 2021 | |
| Ucb, INC. | $733.28 | 2022-2025 | Fintepla, Nayzilam, Briviact |
| Jazz Pharmaceuticals INC. | $271.97 | 2022-2025 | |
| Neurelis, INC. | $258.90 | 2021-2025 | Valtoco |
| Mdd US Operations, LLC | $185.77 | 2023 | Myobloc |
| Acadia Pharmaceuticals INC | $159.88 | 2023-2025 | Daybue |
| Sumitomo Pharma America, INC. | $128.12 | 2023-2024 | Aptiom |
| Livanova USA, INC. | $117.01 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $63.55 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otter Pharmaceuticals, LLC | $61.40 | 2025 | Sympazan |
| Cranial Technologies, INC | $58.91 | 2024-2025 | Doc Band |
| Azurity Pharmaceuticals, INC. | $57.65 | 2025 | Zonisade |
| Catalyst Pharmaceuticals, INC. | $48.25 | 2023-2024 | Fycompa |
| Sk Life Science, INC. | $45.84 | 2020 | |
| Noven Therapeutics, LLC | $39.11 | 2025 | Xelstrym |
| Greenwich Biosciences, INC. | $33.88 | 2021 | |
| Biocodex, INC. | $29.74 | 2023 | Diacomit |
| Abbvie INC. | $26.93 | 2025 | |
| Biomarin Pharmaceutical INC. | $26.35 | 2021 | |
| Immedica Pharma US, INC. | $25.11 | 2025 | Ztalmy |
| Sunovion Pharmaceuticals INC. | $23.76 | 2022 | |
| Itf Therapeutics LLC | $15.06 | 2024 | |
| Aucta Pharmaceuticals, INC. | $14.30 | 2025 | Motpoly Xr |
| Rhodes Pharmaceuticals L.P. | $13.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.